Skip to content

Cannabis: all studies

Page 132 of 287: studies 1,311 to 1,320 of 2,864, newest first. Back to the cannabis overview

Research

Naltrexone does not attenuate the effects of intravenous Δ9-tetrahydrocannabinol in healthy humans.

The International Journal of Neuropsychopharmacology October 2012 Mohini Ranganathan, Michelle Carbuto, Gabriel Braley et al.

Although a wealth of preclinical evidence indicates an interplay between the μ-opioid (MOR) and cannabinoid 1 receptor (CB1R) systems, the precise nature of the cross modulation in humans is unclear. The objective of this study was to evaluate the effects of pretreatment with the MOR antagonist, naltrexone, on the subjective, behavioural and cognitive effects of the CB1R agonist,...

Δ⁹Tetrahydrocannabinol impairs visuo-spatial associative learning and spatial working memory in rhesus macaques.

Journal of Psychopharmacology October 2012 Michael A. Taffe

Cannabis remains the most commonly abused illicit drug and is rapidly expanding in quasi-licit use in some jurisdictions under medical marijuana laws. Effects of the psychoactive constituent Δ⁹tetrahydrocannabinol (Δ⁹THC) on cognitive function remain of pressing concern. Prior studies in monkeys have not shown consistent evidence of memory-specific effects of Δ⁹THC on recognition tasks, and it...

Balanced placebo design with marijuana: pharmacological and expectancy effects on impulsivity and risk taking.

Psychopharmacology October 2012 Jane Metrik, Christopher W Kahler, Brady Reynolds et al.

Marijuana is believed to increase impulsivity and risk taking, but the processes whereby it affects such behaviors are not understood. Indeed, either the pharmacologic effect of delta-9-tetrahydrocannabinol (THC) or the expectancy of receiving it may lead to deficits in cognitive processing and increases in risk taking. We examined the relative effects of expecting to receive active marijuana...

Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers

Psychological Medicine October 1, 2012 Zerrin Atakan, Sagnik Bhattacharyya, Paul Allen et al. 54 citations

BACKGROUND: Cannabis can induce transient psychotic symptoms, but not all users experience these adverse effects. We compared the neural response to Δ9-tetrahydrocannabinol (THC) in healthy volunteers in whom the drug did or did not induce acute psychotic symptoms. Method In a double-blind, placebo-controlled, pseudorandomized design, 21 healthy men with minimal experience of cannabis were...

Patient’s Perceptions of the Cannabis-psychosis Link - A Systematic Review

Current Pharmaceutical Design September 12, 2012 Anna Buadze, Stefan Kaiser, Rudolf Stohler et al. 10 citations

Over the past years a growing research effort has investigated the relation between cannabis use and schizophrenia at a neurobiological, epidemiological and clinical level. A number of systematic reviews and meta analyses have summarized the available evidence in the field. Conversely the patient's perception of the link between cannabis use and psychosis has been under investigation. Since...

Acute Effects of a Single, Oral dose of d9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) Administration in Healthy Volunteers

Current Pharmaceutical Design September 12, 2012 Rocío Martín‐Santos, José Alexandre S. Crippa, Albert Batalla et al. 288 citations

RATIONALE: Animal and humans studies suggest that the two main constituents of cannabis sativa, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) have quite different acute effects. However, to date the two compounds have largely been studied separately. OBJECTIVE: To evaluate and compare the acute pharmacological effects of both THC and CBD in the same human volunteers. METHODS: A...

Long-term behavioral and biochemical effects of an ultra-low dose of Δ9-tetrahydrocannabinol (THC): neuroprotection and ERK signaling.

Experimental Brain Research September 2012 Miriam Fishbein, Sahar Gov, Fadi Assaf et al.

We have previously reported that a single injection of an ultra-low dose of delta-9-tetrahydrocannabinol (THC; the psychoactive ingredient of marijuana) protected the brain from pentylenentetrazole (PTZ)-induced cognitive deficits when applied 1-7 days before or 1-3 days after the insult. In the present study we expanded the protective profile of THC by showing that it protected mice from...

Ovarian hormones and chronic administration during adolescence modify the discriminative stimulus effects of delta-9-tetrahydrocannabinol (Δ⁹-THC) in adult female rats.

Pharmacology, Biochemistry, and Behavior September 2012 Peter J Winsauer, Catalin M Filipeanu, Evangeline M Bailey et al.

Marijuana abuse during adolescence may alter its abuse liability during adulthood by modifying the interoceptive (discriminative) stimuli produced, especially in females due to an interaction with ovarian hormones. To examine this possibility, either gonadally intact or ovariectomized (OVX) female rats received 40 intraperitoneal injections of saline or 5.6 mg/kg of Δ⁹-THC daily during...

Altered cerebral blood flow and neurocognitive correlates in adolescent cannabis users.

Psychopharmacology August 2012 Joanna Jacobus, Diane Goldenberg, Christina E Wierenga et al.

The effects of adolescent marijuana use on the developing brain remain unclear, despite its prevalence. Arterial spin labeling (ASL) is a noninvasive imaging technique that characterizes neurovascular status and cerebral blood flow (CBF), potentially revealing contributors to neuropathological alterations. No studies to date have looked at CBF in adolescent marijuana users. This study examined...

Alterations of theory of mind network activation in chronic cannabis users.

Schizophrenia Research August 2012 Patrik Roser, Silke Lissek, Martin Tegenthoff et al.

Chronic cannabis use is associated with cognitive impairment and has been identified as a risk factor for schizophrenia. Patients with schizophrenia show profound deficits in social cognition such as the ability to attribute mental states to others, referred to as "theory of mind" (ToM). Aberrant activation of the ToM network has been demonstrated across different phases of schizophrenia,...